ATI RN · Pathophysiology · Pathophysiology Practice Exam

Option C: Alloimmune reactions occur when the maternal immune system recognizes fetal antigens as foreign, leading to an immune response. This sensitization can result in conditions such as hemolytic disease of the newborn, where maternal antibodies attack fetal red blood cells, highlighting the significance of understanding maternal-fetal immunology.

Option A: Autoimmune reactions involve the immune system attacking the body's own tissues, which does not apply in this context where the target is fetal antigens.

Option B: Anaphylaxis is a severe allergic reaction typically triggered by allergens, not by the sensitization of the maternal immune system to fetal antigens.

Option D: Allergic reactions are specific responses to environmental antigens, differing from alloimmune reactions that involve recognition of non-self antigens from another individual, such as a fetus.

Takeaways: Understanding alloimmune reactions is crucial in maternal-fetal medicine, as sensitization against fetal antigens can lead to significant complications, requiring appropriate prenatal care and monitoring to manage potential risks.

Option A: Frequent infections and low neutrophil levels indicate a compromised immune system, which can occur in renal failure due to impaired erythropoiesis. The kidneys produce erythropoietin, which stimulates red blood cell production; thus, renal failure leads to anemia and increased susceptibility to infections.

Option B: Fatigue and increased heart rate are common symptoms of anemia but are not specific to impaired erythropoiesis. These signs can also result from various other conditions, including dehydration or heart issues.

Option C: Agitation and changes in cognition may suggest metabolic disturbances or uremia but do not directly indicate impaired erythropoiesis. These symptoms are more related to the accumulation of toxins in renal failure rather than anemia itself.

Option D: Increased blood pressure and peripheral edema are typically associated with fluid overload and hypertension in renal failure, not specifically with impaired erythropoiesis. These findings relate more to the kidneys' inability to regulate fluid balance.

Takeaways: Impaired erythropoiesis in renal failure leads to anemia, which can manifest as frequent infections and low neutrophil levels due to decreased erythropoietin production; thus, monitoring for anemia in chronic kidney disease is essential for patient management.

Option B: Muscular atrophy involves a decrease in muscle cell size, which is a key characteristic of this condition. This process can occur due to various factors, including disuse, aging, or disease, leading to a reduction in the functional capacity of the muscle. Understanding this concept is crucial for nursing assessments and interventions related to muscle health.

Option A: Muscular atrophy does not involve a decrease in the number of muscle cells; rather, it specifically refers to the reduction in the size of existing muscle fibers.

Option C: Vacuoles are cellular structures that may appear in various conditions but are not directly related to the definition or process of muscular atrophy.

Option D: Lipofuscin is a pigment that accumulates in aging cells but does not pertain to the size of muscle cells or the process of atrophy itself.

Takeaways: Understanding that muscular atrophy specifically refers to a decrease in muscle cell size is essential for effective patient care and rehabilitation strategies, particularly in managing muscle wasting conditions and recovery that can impact overall health.

Option A: Raloxifene is indeed a selective estrogen receptor modulator (SERM) that helps prevent bone loss by mimicking estrogen's beneficial effects on bone density. This option accurately describes the medication's primary function in osteoporosis treatment.

Option B: Raloxifene does not decrease bone formation or increase bone resorption; rather, it helps maintain bone density by acting on estrogen receptors. This option misrepresents the mechanism of action of the drug.

Option C: Raloxifene should be taken with food to enhance absorption and minimize gastrointestinal side effects, making this the correct teaching point for the patient regarding medication administration.

Option D: Raloxifene is not typically associated with weight gain and fluid retention, which are more common side effects of other medications. This option mischaracterizes the side effect profile of raloxifene.

Takeaways: Raloxifene serves as a selective estrogen receptor modulator to prevent bone loss, and it should be taken with food to enhance absorption and minimize gastrointestinal side effects, which requires patient education about medication administration prior to treatment.

Option A: Liver function tests should be monitored during androgen therapy for hypogonadism due to the potential hepatotoxic effects of exogenous testosterone. Regular assessment helps identify any liver dysfunction early, ensuring patient safety and effective management of therapy.

Option B: Kidney function tests are not routinely required for monitoring during androgen therapy, as testosterone primarily affects liver function and hematologic parameters rather than renal function.

Option C: Prostate-specific antigen (PSA) monitoring is important in patients receiving androgen therapy, but it is not the primary laboratory test to monitor liver function, which is crucial due to the risk of hepatotoxicity.

Option D: A complete blood count (CBC) can be useful to monitor for polycythemia, a potential side effect of testosterone therapy, but it does not directly assess liver function, which is the primary concern in this context.

Takeaways: Monitoring liver function tests during androgen therapy is essential due to the risk of hepatotoxicity associated with testosterone use, requiring regular assessment to ensure patient safety and effective management.